Two-Day Event Brings Together Top Israeli CEOs and New England Life Sciences Community
NEWTON, Mass.--(BUSINESS WIRE)-- The New England-Israel Business Council (NEIBC), an organization committed to creating business and collaboration opportunities between Israeli and U.S. firms, is convening its 2010 Life Sciences Summit, a high-powered two-day program, on October 18 and 19, that will bring to the U.S. the CEOs of fifteen of the most promising Israeli life sciences companies to present to, and network with, an audience of New England leaders in the life sciences, including executives in leading biotech, pharmaceutical and medical device companies, researchers, health care providers, investment professionals, and others with an interest in the field.
“The word ‘summit’ is often used to describe a meeting between leaders of two nations or communities seeking common understanding and cooperation,” says David Barone, Chairman of the NEIBC Life Sciences Committee. “We feel that it is also the most appropriate title for this event, which is designed to foster greater collaboration between the New England and Israel life sciences communities, two of the leading regions in the world for innovation in this field, as they pursue continuing breakthroughs in diagnosing and treating diseases.”
The 2010 Summit, hosted by Brandeis International Business School, will feature over 25 experts participating in panel discussions and workshops, and one-on-one meetings between delegates and representatives of local life science companies, investors, and research collaborators. The keynote address will be delivered on October 18th by Professor Aaron Ciechanover, a 2004 Nobel Laureate from the prestigious Technion Israel Institute of Technology. A luncheon address on October 19th will be delivered by Paul Levy, CEO of Beth Israel Deaconess Medical Center in Boston.
Israeli companies participating in the summit include:
- Biokine Therapeutics., an emerging biotechnology company developing novel drugs for cancer patients including anti-cancer and stem cells mobilization drugs.
- Dynamix Pharmaceuticals, which is focused on the discovery and development of targeted, small-molecule drugs for cancer and autoimmune disorders.
- Elminda, a developer of technology enabling visualization and characterization of brain network activity in support of neuro-intervention therapies.
- Foamix, a drug development company focused in topical drug and cosmetic delivery.
- MacroCure, which is focused on the development and commercialization of advanced cell therapy products.
- Mazor Surgical Technologies, which has pioneered the development of miniature semi-robotic, bone-mounted positioning systems for a wide range of orthopedic procedures.
- NasVax , which develops improved delivery systems for vaccines and immunotherapeutics.
- NovoCure, which has developed a non-invasive, portable medical device for the treatment of cancer, utilizing low intensity alternating electric fields.
- Protalix Biotherapeutics, which is focused on the development and commercialization of recombinant therapeutic proteins based on a protein expression system.
- Proteologics, a biopharmaceutical company exploiting the UBIQUITIN system for the discovery and development of novel therapeutics.
- Rosetta Genomics, a leading developer of microRNA-based diagnostic tests and therapeutic tools.
- TransPharma Medical, a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing an active transdermal drug delivery technology.
For general information about the summit, go to www.neibc.org/2010summit, email [email protected] or call the New England–Israel Business Council at (617) 610-0077. For sponsorship opportunities, contact Ben Shamir at [email protected] and for partnership information, contact Sara Dolinsky at [email protected].
CONTACT:
Ball Consulting Group, LLC
David Ball, 617-243-9950
M: 617-548-7809
[email protected]
KEYWORDS: United States North America Massachusetts Middle East Israel
INDUSTRY KEYWORDS: Stem Cells Surgery Health Biotechnology Genetics Hospitals Medical Devices Oncology Pharmaceutical General Health
MEDIA:
| Logo |